Our results suggest that immunohistochemical detection of EGFR should be routinely included in the prognostic evaluation of patients with oral cancer, using 10% of EGFR+ tumor cells as a cut-off point to consider a positive case. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.